HPV DNA test


Also found in: Dictionary, Encyclopedia.
Related to HPV DNA test: colposcopy

HPV DNA test

A test to determine whether cancer-causing variants of human papillomavirus (HPV) are present in the endocervix or ectocervix of women undergoing Papanicolaou (Pap) testing.

Patient care

The test is performed by swabbing the cervix and endocervix carefully and then submitting the specimen for laboratory analysis. The test detects the most common types of HPV that may, in some patients, cause cervical cancer. It may be used to follow up abnormal Pap test results, e.g., atypical squamous cells of uncertain significance, or it may be employed in conjunction with Pap testing. Women whose Pap test results are normal and who have a negative HPV test have a very low risk for cervical cancer. Routine HPV screening should be performed for sexually active woman over the age of 30, but not before.

Synonym: hybrid capture test
References in periodicals archive ?
Objections to the use of the HPV DNA test as a primary screen include the following:
The cost of the Hybrid Capture 2 High Risk HPV DNA Test varies, but Medicare reimbursement is around $50, a Digene spokesman said.
In the present study we did not directly compare our mRNA HPV results with those of a HPV DNA test, but in a meta-analysis by Arbyn et al, (5) lower specificity has been reported for triage of women with LSIL, when using Hybrid Capture 2 or HPV DNA PCR.
Product Name: Digene Hybrid Capture 2 High-Risk HPV DNA Test
(a) Hybrid Capture tube-based HPV DNA test of a direct swab obtained cervical specimen transferred to a tube of specimen transport media.[2]
There are a number of other areas for which HPV testing should not be done but are not mentioned in the HPV DNA Test Utilization Statement.
The cost of the Hybrid Capture 2 High-Risk HPV DNA Test varies, but Medicare reimbursement is around $50, a Digene spokesman said.
The purpose of this study was to determine the efficacy of a repeat Pap smear and an HCT HPV DNA test for detecting the presence of cervical neoplasia in women with recent Pap smear reports of ASCUS or LSIL.
The hc2 High-Risk HPV DNA Test is an FDA-approved HPV test for primary screening with the DNAwithPap test for cervical cancer and its precursors in women age 30+.
(1) Significantly, this latter algorithm recommends the follow-up of women with a negative HPV DNA test with cytology at 12 months and not at a six-month interval.
The Hybrid Capture 2 High-Risk HPV DNA Test ([hc.sub.2]) is an FDA-approved HPV test for primary screening with the Pap test for cervical cancer and its precursors in women age 30 and older, called DNAwithPap.